Mobile

Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002631-33

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the change in BASDAI score

Critère d'inclusion

  • Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA)

Liens